Novo Nordisk Secured Rights for New Dual Agonist Drug
The company acquired global rights to a new oral diabetes and obesity drug that is nearing clinical trials.
Updated on Sept. 29, 2026 in Diabetes
Live Poll
Do you trust that pharmaceutical investment in new weight-loss drugs will lead to better patient outcomes?
Novo Nordisk has entered into an exclusive licensing agreement with Hengrui Pharma to develop and commercialize HRS-1596. This potential $2.6 billion deal targets an oral, once-weekly dual agonist for obesity and type 2 diabetes.
Why it matters
This partnership seeks to expand the landscape of treatments for metabolic conditions by advancing a next-generation oral medication. It marks a significant investment in the pipeline of GLP-1 and GIP dual receptor agonists.
The agreement centers on HRS-1596, a phase 1-ready dual GLP-1 and GIP receptor agonist, which has already received regulatory approval to initiate initial clinical testing in China.
The players
Novo Nordisk
A global pharmaceutical company specializing in treatments for diabetes, obesity, and other chronic diseases.
Hengrui Pharma
A pharmaceutical manufacturer focused on research and development in the areas of oncology and metabolic health.
The details
HRS-1596 is designed as a once-weekly oral medication that acts on both GLP-1 and GIP receptors. By targeting these two pathways simultaneously, the therapy aims to regulate blood glucose and assist in weight management through the body's metabolic signaling systems.
Timeline
September 29, 2026: Novo Nordisk and Hengrui Pharma announced the partnership.
Fourth quarter of 2026: The transaction is expected to close.
Health Landscape
This agreement reflects the ongoing trend toward developing once-weekly oral treatments for metabolic health. It sits within the broader research evolution of targeting multiple hormonal pathways to improve outcomes for obesity and type 2 diabetes.
This development represents early-stage research and will not impact current treatment options or clinical practice for patients in the near term. As the drug moves through future trials, stay informed by discussing new metabolic research developments with your endocrinologist.
The takeaway
This partnership highlights the industry's commitment to finding more convenient, oral alternatives to injectable metabolic medications. Patients should continue to monitor updates from their healthcare providers regarding the evolution of long-term weight and blood glucose management options.
Further reading
For more on emerging options in metabolic care, visit the Diabetes section.
Live Poll
Do you trust that pharmaceutical investment in new weight-loss drugs will lead to better patient outcomes?
